{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:04:08Z","timestamp":1789693448021,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373396"],"award-info":[{"award-number":["82373396"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.cellsig.2026.112843","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:37:51Z","timestamp":1787614671000},"page":"112843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Repurposing minocycline to target FOXA1 and its mutants in prostate Cancer"],"prefix":"10.1016","volume":"148","author":[{"given":"Ziyin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingshuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoya","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cellsig.2026.112843_bb0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"10013","key":"10.1016\/j.cellsig.2026.112843_bb0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","article-title":"Prostate cancer","volume":"387","author":"Attard","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cellsig.2026.112843_bb0015","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.trecan.2020.04.010","article-title":"Advanced prostate Cancer: treatment advances and future directions","volume":"6","author":"Swami","year":"2020","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112843_bb0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.21873\/invivo.14197","article-title":"FOXA1 alterations in prostate Cancer: expression, mutation classes, and copy number changes","volume":"40","author":"Lehrer","year":"2026","journal-title":"In Vivo"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112843_bb0025","first-page":"58","article-title":"Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance","volume":"6","author":"Gao","year":"2025","journal-title":"J. Natl. Cancer Cent."},{"issue":"12","key":"10.1016\/j.cellsig.2026.112843_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122653","article-title":"Androgen receptor signaling pathway in prostate cancer: from genetics to clinical applications","volume":"9","author":"Aurilio","year":"2020","journal-title":"Cells"},{"issue":"21","key":"10.1016\/j.cellsig.2026.112843_bb0035","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1101\/gad.176826.111","article-title":"Pioneer transcription factors: establishing competence for gene expression","volume":"25","author":"Zaret","year":"2011","journal-title":"Genes Dev."},{"issue":"7406","key":"10.1016\/j.cellsig.2026.112843_bb0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"issue":"7801","key":"10.1016\/j.cellsig.2026.112843_bb0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.cellsig.2026.112843_bb0050","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.cellsig.2026.112843_bb0055","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cellsig.2026.112843_bb0060","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112843_bb0065","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cellsig.2026.112843_bb0070","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bbi.2011.01.015","article-title":"Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression","volume":"25","author":"Markovic","year":"2011","journal-title":"Brain Behav. Immun."},{"issue":"5","key":"10.1016\/j.cellsig.2026.112843_bb0075","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1007\/s00210-023-02839-1","article-title":"Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review","volume":"397","author":"Rezaei","year":"2024","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"6141","key":"10.1016\/j.cellsig.2026.112843_bb0080","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1233606","article-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"341","author":"Molina","year":"2013","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.cellsig.2026.112843_bb0085","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/nprot.2014.138","article-title":"The cellular thermal shift assay for evaluating drug target interactions in cells","volume":"9","author":"Jafari","year":"2014","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112843_bb0090","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13104-015-1000-8","article-title":"Limitations of the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays","volume":"8","author":"Van Tonder","year":"2015","journal-title":"BMC. Res. Notes"},{"issue":"7","key":"10.1016\/j.cellsig.2026.112843_bb0095","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1158\/0008-5472.CAN-05-3627","article-title":"Contributions of human tumor xenografts to anticancer drug development","volume":"66","author":"Sausville","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112843_bb0100","doi-asserted-by":"crossref","unstructured":"Hwang, J.H., et al., CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer. Cell Rep., 2019. 29(8): p. 2355\u20132370. (e6).","DOI":"10.1016\/j.celrep.2019.10.068"},{"issue":"12","key":"10.1016\/j.cellsig.2026.112843_bb0105","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/emboj.2011.154","article-title":"Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth","volume":"30","author":"Chen","year":"2011","journal-title":"EMBO J."},{"issue":"21","key":"10.1016\/j.cellsig.2026.112843_bb0110","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.1158\/0008-5472.CAN-11-1882","article-title":"Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer","volume":"71","author":"Zhang","year":"2011","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112843_bb0115","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ajpath.2011.10.021","article-title":"FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer","volume":"180","author":"Gerhardt","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112843_bb0120","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.prnil.2025.12.002","article-title":"AR-V7 expression in primary non-metastatic prostate cancer and its role in disease progression following initial therapy: a systematic review and meta-analysis","volume":"14","author":"Quintanilha","year":"2026","journal-title":"Prostate Int."},{"issue":"30","key":"10.1016\/j.cellsig.2026.112843_bb0125","doi-asserted-by":"crossref","first-page":"29782","DOI":"10.18632\/oncotarget.4927","article-title":"FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer","volume":"6","author":"Jones","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.cellsig.2026.112843_bb0130","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.molonc.2015.02.010","article-title":"Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells\u2192 androgen receptor (AR)\u2192 miRNA32 signals","volume":"9","author":"Dang","year":"2015","journal-title":"Mol. Oncol."},{"issue":"19","key":"10.1016\/j.cellsig.2026.112843_bb0135","article-title":"Minocycline mitigates sepsis-induced neuroinflammation and promotes recovery in male mice: insights into neuroprotection and inflammatory modulation","volume":"12","author":"Hosseini","year":"2024","journal-title":"Phys. Rep."},{"issue":"7765","key":"10.1016\/j.cellsig.2026.112843_bb0140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41586-019-1318-9","article-title":"FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes","volume":"571","author":"Adams","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.cellsig.2026.112843_bb0145","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41422-019-0203-2","article-title":"Forkhead domain mutations in FOXA1 drive prostate cancer progression","volume":"29","author":"Gao","year":"2019","journal-title":"Cell Res."},{"issue":"15","key":"10.1016\/j.cellsig.2026.112843_bb0150","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"23","key":"10.1016\/j.cellsig.2026.112843_bb0155","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","article-title":"The role of lineage plasticity in prostate cancer therapy resistance","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112843_bb0160","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1038\/s41467-018-06067-7","article-title":"Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112843_bb0165","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","article-title":"Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines","volume":"73","author":"Li","year":"2013","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.cellsig.2026.112843_bb0170","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1515\/hsz-2014-0149","article-title":"Analysis of androgen and anti-androgen regulation of KLK-related peptidase 2, 3, and 4 alternative transcripts in prostate cancer","volume":"395","author":"Lai","year":"2014","journal-title":"Biol. Chem."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112843_bb0175","doi-asserted-by":"crossref","first-page":"21750","DOI":"10.1038\/s41598-020-78798-x","article-title":"Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease","volume":"10","author":"Smith","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.cellsig.2026.112843_bb0180","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14728222.11.4.507","article-title":"FOXA1 as a therapeutic target for breast cancer","volume":"11","author":"Nakshatri","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.cellsig.2026.112843_bb0185","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.18632\/aging.202247","article-title":"Silencing LINC00482 inhibits tumor-associated inflammation and angiogenesis through down-regulation of MMP-15 via FOXA1 in bladder cancer","volume":"13","author":"Wang","year":"2020","journal-title":"Aging (Albany NY)"}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826005012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826005012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:20:41Z","timestamp":1789690841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656826005012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":37,"alternative-id":["S0898656826005012"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112843","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing minocycline to target FOXA1 and its mutants in prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112843"}}